Drug Buyers Oppose Gilead and Teva’s Request to Consolidate Appeals on HIV Medications

Drug buyers who allege that Gilead Sciences Inc. and Teva Pharmaceuticals delayed the release of generic versions of HIV medications have told the Ninth Circuit that it would be unfair to grant the companies’ request for a single brief addressing the 17 appeals filed following a jury’s rejection of these claims last year. This dispute highlights ongoing tensions in the pharmaceutical industry regarding access to more affordable generic drugs and the legal strategies employed to address these issues. For a deeper dive into the ongoing legal battle, details can be found here.